(Nasdaq: MDCX) Has Two Clinical Programs Targeting An Estimated $8Bn TAM

Medicus Pharma Ltd. (Nasdaqn: MDCX) received a regulatory authorization

Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on Behalf of Medicus Pharma Ltd. (Nasdaq: MDCX) Has Two Clinical Programs Targeting An Estimated $8Bn TAM *Click Here To Get Our Alerts Faster Via SMS* July 31st Dear Reader, Medicus Pharma Ltd. (Nasdaqn: MDCX) received a regulatory authorization on July 27th, 2026, that few market watchers will want to ignore. The agency issued a "Study May Proceed" letter for SKNJCT-005, granting the company clearance to begin an NDA-enabling Phase 2b registrational clinical trial of SkinJect® in patients with Gorlin Syndrome. That authorization marks a meaningful step forward — from exploratory Phase 2 evidence into registrational territory. Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited disorder that forces patients into a relentless cycle of surgical interventions. Those affected can develop dozens to over 1,000 basal cell carcinoma lesions across a lifetime, often beginning in childhood or adolescence. To date, there is no FDA-approved lesion-directed treatment for this patient population. SkinJect was designed to fill that gap. The therapy is a dissolvable microneedle array patch that delivers doxorubicin chemotherapy directly into basal cell carcinoma tumors. Phase 2 data from SKNJCT-003, which enrolled 90 patients at nine U.S. clinical sites, showed 64% clinical clearance and 55% histological clearance at Day 57 in the 200 mcg dose group, with zero treatment-related serious adverse events. The dataset established a clear dose-response relationship — what the company has described as "decision-grade" evidence. Registrational study SKNJCT-005 will enroll up to 50 Gorlin Syndrome patients, with treatment targeting two to four lesions at a time. Extended patient follow-up of at least two years is required by the FDA — a protocol enhancement that management views as reinforcing durability evaluation rather than a constraint. Executive Chairman and Medicus Pharma CEO, Dr. Raza Bokhari, called the clearance "a significant regulatory milestone." Concurrently, MDCX is advancing Teverelix, a long-acting injectable GnRH antagonist targeting advanced prostate cancer in patients with elevated cardiovascular risk. The FDA granted "Study May Proceed" clearance for a Teverelix Phase 2b dose-optimization study in February 2026, and the company has filed a substantial modification application through the EU Clinical Trials Information System for a European expansion. Between the two clinical programs, MDCX estimates approximately $8Bn in total addressable markets across multiple indications. SkinJect was designed to fill that gap. The therapy is a dissolvable microneedle array patch that delivers doxorubicin chemotherapy directly into basal cell carcinoma tumors. Phase 2 data from SKNJCT-003, which enrolled 90 patients at nine U.S. clinical sites, showed 64% clinical clearance and 55% histological clearance at Day 57 in the 200 mcg dose group, with zero treatment-related serious adverse events. The dataset established a clear dose-response relationship — what the company has described as "decision-grade" evidence. Registrational study SKNJCT-005 will enroll up to 50 Gorlin Syndrome patients, with treatment targeting two to four lesions at a time. Extended patient follow-up of at least two years is required by the FDA — a protocol enhancement that management views as reinforcing durability evaluation rather than a constraint. Executive Chairman and Medicus Pharma CEO, Dr. Raza Bokhari, called the clearance "a significant regulatory milestone." Concurrently, MDCX is advancing Teverelix, a long-acting injectable GnRH antagonist targeting advanced prostate cancer in patients with elevated cardiovascular risk. The FDA granted "Study May Proceed" clearance for a Teverelix Phase 2b dose-optimization study in February 2026, and the company has filed a substantial modification application through the EU Clinical Trials Information System for a European expansion. Between the two clinical programs, MDCX estimates approximately $8Bn in total addressable markets across multiple indications. Company Breakdown: Medicus Pharma Ltd. Medicus Pharma Ltd. is a precision-focused biotech company with operations spanning three continents. The company follows a "de-risk and partner" model: advance novel therapeutic assets through Phase 2 proof-of-concept clinical trials, then seek licensing or commercialization partnerships with established pharmaceutical companies. Its lead asset, SkinJect (D-MNA), is being developed under the FDA's 505(b)(2) regulatory pathway, which allows the company to draw on existing doxorubicin safety data and may compress the review timeline. Teverelix came into the pipeline through the August 2025 acquisition of UK-based Antev Ltd., which added a second late-stage program targeting men with advanced prostate cancer and high cardiovascular risk. Phase 1 Teverelix data presented at AACE 2026 demonstrated predictable, dose-dependent hormone suppression with no unexpected safety signals. Strategic collaborations include a partnership with Reliant AI Inc. on clinical analytics and a memorandum of understanding with Helix Nanotechnologies for mRNA vaccine applications. 5 Potential Catalysts Send (Nasdaq: MDCX) To Our #1 Watchlist Spot 1. FDA Clearance For Registrational Trial Advances Path Toward NDA Filing. The July 27th, 2026 authorization for SKNJCT-005 positions MDCX as the first company moving a lesion-directed therapy toward a potential NDA submission specifically for Gorlin Syndrome — a condition with no currently approved lesion-directed treatment option. 2. Orphan Drug Application Could Deliver Seven-Year Market Exclusivity. The April 2026 Orphan Drug Designation application for SkinJect in Gorlin Syndrome, if granted, would provide MDCX a potential $5Mn-plus NDA fee exemption alongside seven years of market exclusivity following FDA approval. 3. Rare Pediatric Disease Submission May Unlock A Priority Review Voucher. MDCX filed for Rare Pediatric Disease Designation in June 2026 — a status that, if awarded, could make the company eligible for a Priority Review Voucher upon NDA approval, a regulatory asset with documented value in pharmaceutical licensing transactions. 4. Teverelix Moving Forward On U.S. And European Regulatory Tracks.With FDA Phase 2b clearance secured in February 2026 and an EU regulatory submission filed through the CTIS platform, MDCX is pursuing Teverelix across two major pharmaceutical markets simultaneously, targeting a combined addressable market the company estimates at approximately $6Bn. 5. 505(b)(2) Filing Route May Compress Timelines Versus Standard NDA. The FDA confirmation the 505(b)(2) pathway for SkinJect means MDCX can incorporate existing doxorubicin safety data into its regulatory submission — a structural advantage that may reduce both cost and time-to-decision relative to a new chemical entity pathway. The Bottom Line Medicus Pharma Ltd. (Nasdaq: MDCX) isn't making headlines for the sake of it. Every material announcement from this company over the past 18 months has carried genuine regulatory or clinical substance: Phase 2 data packages, FDA clearances, Orphan Drug applications, conference presentations, and now a registrational trial authorization for a rare disease with no existing approved therapy. That is a meaningful pattern to recognize. For those watching the biotech space for names with multiple near-term regulatory milestones and a pipeline built on clinical validation, MDCX is one worth keeping on your radar as 2026 continues to develop. We are kicking off coverage on Medicus Pharma Ltd. (Nasdaq: MDCX). Be on the lookout — updates will be heading out soon. Talk again shortly. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer More Sources: MDCX Website (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Fierce Investor | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice